Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
- PMID: 16596572
- DOI: 10.1002/sim.2528
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Abstract
For rare outcomes, meta-analysis of randomized trials may be the only way to obtain reliable evidence of the effects of healthcare interventions. However, many methods of meta-analysis are based on large sample approximations, and may be unsuitable when events are rare. Through simulation, we evaluated the performance of 12 methods for pooling rare events, considering estimability, bias, coverage and statistical power. Simulations were based on data sets from three case studies with between five and 19 trials, using baseline event rates between 0.1 and 10 per cent and risk ratios of 1, 0.75, 0.5 and 0.2. We found that most of the commonly used meta-analytical methods were biased when data were sparse. The bias was greatest in inverse variance and DerSimonian and Laird odds ratio and risk difference methods, and the Mantel-Haenszel (MH) odds ratio method using a 0.5 zero-cell correction. Risk difference meta-analytical methods tended to show conservative confidence interval coverage and low statistical power at low event rates. At event rates below 1 per cent the Peto one-step odds ratio method was the least biased and most powerful method, and provided the best confidence interval coverage, provided there was no substantial imbalance between treatment and control group sizes within trials, and treatment effects were not exceptionally large. In other circumstances the MH OR without zero-cell corrections, logistic regression and the exact method performed similarly to each other, and were less biased than the Peto method.
Similar articles
-
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.Stat Med. 2004 May 15;23(9):1351-75. doi: 10.1002/sim.1761. Stat Med. 2004. PMID: 15116347
-
Estimators and confidence intervals for the marginal odds ratio using logistic regression and propensity score stratification.Stat Med. 2010 Mar 30;29(7-8):760-9. doi: 10.1002/sim.3811. Stat Med. 2010. PMID: 20213703
-
Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Clin Trials. 2008. PMID: 18375649
-
Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):98-101. doi: 10.1510/icvts.2008.198325. Epub 2009 Apr 20. Interact Cardiovasc Thorac Surg. 2009. PMID: 19380335 Review.
-
Evidence-based dermatology: number needed to treat and its relation to other risk measures.J Am Acad Dermatol. 2007 Apr;56(4):664-71. doi: 10.1016/j.jaad.2006.08.024. Epub 2006 Oct 27. J Am Acad Dermatol. 2007. PMID: 17367615 Review.
Cited by
-
The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis.J Urol. 2013 Dec;190(6):2153-60. doi: 10.1016/j.juro.2013.05.058. Epub 2013 May 30. J Urol. 2013. PMID: 23727412 Free PMC article.
-
Meta-Analysis of Rare Binary Adverse Event Data.J Am Stat Assoc. 2012 Jun 1;107(498):555-567. doi: 10.1080/01621459.2012.664484. J Am Stat Assoc. 2012. PMID: 23734068 Free PMC article.
-
Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials.Hepat Mon. 2016 Mar 6;16(3):e28537. doi: 10.5812/hepatmon.28537. eCollection 2016 Mar. Hepat Mon. 2016. PMID: 27226796 Free PMC article. Review.
-
Hospital at home: home-based end-of-life care.Cochrane Database Syst Rev. 2021 Mar 16;3(3):CD009231. doi: 10.1002/14651858.CD009231.pub3. Cochrane Database Syst Rev. 2021. PMID: 33721912 Free PMC article.
-
Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis.JAMA Oncol. 2022 Oct 13;8(11):1635-43. doi: 10.1001/jamaoncol.2022.4327. Online ahead of print. JAMA Oncol. 2022. PMID: 36227613 Free PMC article.